Literature DB >> 31240523

A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials.

Saba S Shaikh1,2, Priya U Kumthekar3, Nisha A Mohindra3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31240523     DOI： 10.1007/s11060-019-03219-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  9 in total

Review 1.  Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Authors:  D Ross Camidge; Eudocia Q Lee; Nancy U Lin; Kim Margolin; Manmeet S Ahluwalia; Martin Bendszus; Susan M Chang; Janet Dancey; Elisabeth G E de Vries; Gordon J Harris; F Stephen Hodi; Andrew B Lassman; David R Macdonald; David M Peereboom; David Schiff; Ricardo Soffietti; Martin J van den Bent; Jeffrey S Wefel; Patrick Y Wen
Journal:  Lancet Oncol       Date:  2018-01       Impact factor: 41.316

2.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

3.  Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer.

Authors:  Jie Zhou; Zhihua Gong; Qingzhu Jia; Yan Wu; Zhen-Zhou Yang; Bo Zhu
Journal:  Biochem Biophys Res Commun       Date:  2018-03-17       Impact factor: 3.575

4.  Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma.

Authors:  Lukas W Pfannenstiel; Corey McNeilly; Chaomei Xiang; Kai Kang; Claudia Marcella Diaz-Montero; Jennifer S Yu; Brian R Gastman
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

5.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.

Authors:  Clément Gauvain; Enora Vauléon; Christos Chouaid; Emilie Le Rhun; Laurence Jabot; Arnaud Scherpereel; Florent Vinas; Alexis Benjamin Cortot; Isabelle Monnet
Journal:  Lung Cancer       Date:  2017-12-14       Impact factor: 5.705

8.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

Authors:  Nancy U Lin; Tatiana Prowell; Antoinette R Tan; Marina Kozak; Oliver Rosen; Laleh Amiri-Kordestani; Julia White; Joohee Sul; Louise Perkins; Katherine Beal; Richard Gaynor; Edward S Kim
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

9.  Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy.

Authors:  David J Pinato; Robert J Shiner; Solomon D T White; James R M Black; Pritesh Trivedi; Justin Stebbing; Rohini Sharma; Francesco A Mauri
Journal:  Oncoimmunology       Date:  2016-07-22       Impact factor: 8.110
  9 in total
  1 in total

Review 1.  Polymeric Systems for Cancer Immunotherapy: A Review.

Authors:  Thai Minh Duy Le; A-Rum Yoon; Thavasyappan Thambi; Chae-Ok Yun
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.